Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
10.1007/s13238-010-0057-3
- Author:
Zhiyong LOU
1
;
Xiaoxue ZHANG
Author Information
1. Laboratory of Structural Biology, Tsinghua University, Beijing 100084, China. louzy@xtal.tsinghua.edu.cn
- Publication Type:Journal Article
- MeSH:
Bacterial Proteins;
antagonists & inhibitors;
chemistry;
genetics;
metabolism;
Crystallography, X-Ray;
Drug Discovery;
Genomics;
Models, Molecular;
Molecular Targeted Therapy;
Mycobacterium tuberculosis;
drug effects;
genetics;
metabolism;
Protein Conformation
- From:
Protein & Cell
2010;1(5):435-442
- CountryChina
- Language:English
-
Abstract:
Mycobacterium tuberculosis, which belongs to the genus Mycobacterium, is the pathogenic agent for most tuberculosis (TB). As TB remains one of the most rampant infectious diseases, causing morbidity and death with emergence of multi-drug-resistant and extensively-drug-resistant forms, it is urgent to identify new drugs with novel targets to ensure future therapeutic success. In this regards, the structural genomics of M. tuberculosis provides important information to identify potential targets, perform biochemical assays, determine crystal structures in complex with potential inhibitor(s), reveal the key sites/residues for biological activity, and thus validate drug targets and discover novel drugs. In this review, we will discuss the recent progress on novel targets for structure-based anti-M. tuberculosis drug discovery.
